Uni-Bio Science to conduct diabetes study in China

By Elaine Rigoli

Tampa, Fla., June 28 - Uni-Bio Science Group Ltd. said Wednesday that the State Food and Drug Administration (SFDA) of the People's Republic of China has granted its approval to conduct a clinical study of recombinant Exendin-4 for injection for the treatment of type 2 diabetes.

Patient dosing will begin in July and preliminary data is expected by the end of 2006, according to a news release.

The company said the clinical study could form the basis of an application to the SFDA for registration as a class I prescription new drug.

Exendin is jointly researched by Dongguan Shi Bo Kang Jian Pharmaceutical Technology Co., Ltd., a member of Uni-Bio, with an independent research institution in China.

Uni-Bio Science, formerly known as New Spring Holdings, is an investment holding company located in Hong Kong.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.